英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
Gehrig查看　Gehrig　在百度字典中的解释百度英翻中〔查看〕
Gehrig查看　Gehrig　在Google字典中的解释Google英翻中〔查看〕
Gehrig查看　Gehrig　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated . . .
    We randomly assigned patients with untreated BRAF V600E–mutated metastatic colorectal cancer to receive EC, EC+mFOLFOX6, or standard care The two primary end points were objective response
  • BREAKWATER: Primary analysis of first-line (1L) encorafenib . . .
    BREAKWATER: Primary analysis of first-line (1L) encorafenib + cetuximab (EC) + FOLFIRI in BRAF V600E-mutant metastatic colorectal cancer (mCRC) If you have the appropriate software installed, you can download article citation data to the citation manager of your choice Simply select your manager software from the list below and click Download
  • Updates in BRAF V600E-Mutated Metastatic Colorectal Cancer
    Interview Summary Colorectal cancer (CRC) is the third most common cancer worldwide, and the second leading cause of cancer death Approximately one in five patients with CRC present with metastatic disease at diagnosis The BRAF V600E mutation occurs in 8–12% of patients with metastatic colorectal cancer (mCRC), and is characterised by an aggressive clinical course and poor prognosis This
  • RAS BRAF wild-type metastatic high-methylated colorectal . . .
    Metastatic colorectal cancer (mCRC) differs clinically based on RAS and BRAF mutations or DNA methylation However, in mCRC, the prognostic value and biological characteristics of genome-wide DNA
  • Upfront Modified FOLFOXIRI Plus Panitumumab for RAS BRAF Wild . . .
    We report 5-year results of the phase III randomized TRIPLETE study Eligible patients with RAS BRAF wild-type metastatic colorectal cancer (mCRC) received first-line modified fluorouracil, leucovo
  • BRAFV600E mutant metastatic colorectal cancer: Current . . .
    Abstract Detection of the BRAF V600E mutation has important genetic, prognostic, and therapeutic implications for patients with metastatic colorectal cancer (mCRC), identifying a subgroup of patients who derive modest benefit from standard treatments and have extremely poor prognosis
  • Encorafenib, cetuximab and chemotherapy in BRAF-mutant . . .
    Encorafenib + cetuximab (EC) is approved for previously treated BRAF V600E-mutant metastatic colorectal cancer (mCRC) based on the BEACON phase 3 study Historically, first-line treatment of BRAF
  • FDA Fully Approves Braftovi Combo for BRAF V600E Metastatic . . .
    The U S FDA has granted traditional approval to Braftovi with Erbitux and chemo for adults with BRAF V600E metastatic colorectal cancer
  • Phase III trial results supported recent FDA approval for . . .
    Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy regimen, according to results from the Phase III BREAKWATER trial led by researchers at The University of Texas MD Anderson Cancer Center
  • Management of BRAF-mutant metastatic colorectal cancer: a . . .
    Colorectal cancer (CRC) is still a leading cause of cancer-related deaths in the United States and worldwide, despite recent improvements in cancer management CRC, like many malignancies, is a heterogeneous disease, with subtypes characterized by genetic alterations One common mutation in CRC is in the BRAF gene (most commonly V600E substitution) This occurs in ∼10% of patients with





中文字典-英文字典  2005-2009